{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:47:07Z","timestamp":1792090027868,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100024219","name":"RedHill Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100024219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.03.001","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:45:04Z","timestamp":1773953104000},"page":"822-832","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08\/14)"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-6555","authenticated-orcid":false,"given":"S.","family":"Gillessen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Gobat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pereira Mestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hermanns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.I.","family":"Rothschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Mingrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ciriolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Erdmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sch\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mamot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Bohanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Omlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Ribi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mazzucchelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Barizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.","family":"Horvath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sch\u00e4r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-M.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pollak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-7888","authenticated-orcid":false,"given":"F.","family":"Turco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Rothermundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.03.001_b0005","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.001_b0010","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.03.001_b0015","first-page":"1617","article-title":"Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study","volume":"20","author":"Wright","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.euo.2026.03.001_b0020","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1158\/1535-7163.MCT-09-1186","article-title":"Metformin in cancer therapy: a new perspective for an old antidiabetic drug?","volume":"9","author":"Ben Sahra","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.euo.2026.03.001_b0025","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","article-title":"Metformin and reduced risk of cancer in diabetic patients","volume":"330","author":"Evans","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.03.001_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103543","article-title":"Obesity and prostate cancer: A narrative review","volume":"169","author":"Wilson","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.euo.2026.03.001_b0035","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/aje\/kwn190","article-title":"Antidiabetic medication and prostate cancer risk: a population-based case-control study","volume":"168","author":"Murtola","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.euo.2026.03.001_b0040","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41598-018-38285-w","article-title":"The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis","volume":"9","author":"He","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.03.001_b0045","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","article-title":"Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09)","volume":"66","author":"Rothermundt","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.001_b0050","doi-asserted-by":"crossref","first-page":"831.e1","DOI":"10.1016\/j.urolonc.2021.05.020","article-title":"Repurposing metformin as anticancer drug: randomized controlled trial in advanced prostate cancer (MANSMED)","volume":"39","author":"Alghandour","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.03.001_b0055","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejca.2022.04.005","article-title":"Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: a meta-analysis of AFFIRM, PREVAIL and PROSPER","volume":"170","author":"Joshua","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.03.001_b0060","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1002\/cncr.31973","article-title":"Meaningful differences and validity for the NCCN\/FACT-P Symptom Index: an analysis of the ALSYMPCA data","volume":"125","author":"Beaumont","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.03.001_b0065","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singap"},{"key":"10.1016\/j.euo.2026.03.001_b0070","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.suponc.2010.12.004","article-title":"Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form","volume":"9","author":"Mathias","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1016\/j.euo.2026.03.001_b0075","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-023-00666-2","article-title":"PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer","volume":"27","author":"Scheinberg","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.03.001_b0080","article-title":"A prospective investigation of PTEN loss and ERG expression in lethal prostate cancer","volume":"108","author":"Ahearn","year":"2016","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2026.03.001_b0085","doi-asserted-by":"crossref","first-page":"8540","DOI":"10.3390\/ijms21228540","article-title":"Current status and application of metformin for prostate cancer: A comprehensive review","volume":"21","author":"Ahn","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.03.001_b0090","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1158\/1940-6207.CAPR-10-0175","article-title":"Metformin and other biguanides in oncology: advancing the research agenda","volume":"3","author":"Pollak","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"10.1016\/j.euo.2026.03.001_b0095","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1038\/onc.2014.25","article-title":"Targeting autophagy overcomes Enzalutamide resistance in castration-resistant prostate cancer cells and improves therapeutic response in a xenograft model","volume":"33","author":"Nguyen","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.euo.2026.03.001_b0100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.eururo.2023.07.016","article-title":"Metformin overcomes the consequences of NKX3.1 loss to suppress prostate cancer progression","volume":"85","author":"Papachristodoulou","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.03.001_b0105","doi-asserted-by":"crossref","first-page":"161","DOI":"10.21037\/atm.2017.03.107","article-title":"Morbidity and mortality associated with obesity","volume":"5","author":"Abdelaal","year":"2017","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.euo.2026.03.001_b0110","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/s41391-021-00418-0","article-title":"The obesity paradox in metastatic castration-resistant prostate cancer","volume":"25","author":"Martini","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.03.001_b0115","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/pcan.2015.64","article-title":"Body mass index and mortality in prostate cancer patients: a dose-response meta-analysis","volume":"19","author":"Zhong","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.03.001_b0120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/pcan.2008.36","article-title":"The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer","volume":"12","author":"Armstrong","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.euo.2026.03.001_b0125","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bju.14193","article-title":"Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database","volume":"122","author":"Vidal","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2026.03.001_b0130","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.1200\/JCO.2016.66.7311","article-title":"Body mass index and metastatic renal cell carcinoma: clinical and biological correlations","volume":"34","author":"Albiges","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.03.001_b0135","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.03.001_b0140","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/jnci\/djt310","article-title":"An epidemiologic and genomic investigation into the obesity paradox in renal cell carcinoma","volume":"105","author":"Hakimi","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2026.03.001_b0145","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1470-2045(19)30797-1","article-title":"Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study","volume":"21","author":"Sanchez","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.03.001_b0150","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1158\/1541-7786.MCR-18-0409","article-title":"SPHK1 is a novel target of metformin in ovarian cancer","volume":"17","author":"Hart","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.euo.2026.03.001_b0155","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.annonc.2025.10.004","article-title":"Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study","volume":"37","author":"Fizazi","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.03.001_b0160","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(25)00231-1","article-title":"Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol","volume":"26","author":"Gillessen","year":"2025","journal-title":"Lancet Oncol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112600060X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258893112600060X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:47:50Z","timestamp":1789577270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258893112600060X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S258893112600060X"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.001","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzalutamide Plus Metformin Versus Enzalutamide Alone in Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 2 Trial (SAKK 08\/14)","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}